Obagi Medical (OMPI) Guides Q1, FY12

March 8, 2012 4:39 PM EST
Obagi Medical Products (Nasdaq: OMPI) sees Q1 EPS of 10-11 cents on sales of $27-$29 million. The Street is currently looking for EPS of 20 cents on sales of $28.05 million.

The company expects FY12 EPS from core operations of 89-91 cents, vs. the consensus estimate of 89 cents.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Guidance